Newron Pharmaceuticals SpAXSWX:NWRN 62 Current Ratio is 0.76 as of Dec. 2025, which is 89% below its 10-year median of 6.89. GuruFocus rates XSWX:NWRN with a GF Score™ of 62/100 and a GF Value™ of CHF12.92 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Newron Pharmaceuticals SpA ranks worse than 87.75% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Newron Pharmaceuticals SpA's current ratio for the quarter that ended in Dec. 2025 was 0.76.
Newron Pharmaceuticals SpA has a current ratio of 0.76. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Newron Pharmaceuticals SpA has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Newron Pharmaceuticals SpA's Current Ratio or its related term are showing as below:
XSWX:NWRN'
s Current Ratio Range Over the Past 10 Years
Min: 0.68 Med: 6.89 Max: 15.4
Current: 0.76
During the past 13 years, Newron Pharmaceuticals SpA's highest Current Ratio was 15.40. The lowest was 0.68. And the median was 6.89.
XSWX:NWRN's Current Ratio is ranked worse than 87.75% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs XSWX:NWRN: 0.76
Newron Pharmaceuticals SpA (XSWX:NWRN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Newron Pharmaceuticals SpA Current Ratio Related Terms
Newron Pharmaceuticals SpA Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NWRN vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Current Ratio distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Current Ratio of 0.76 as of Dec. 2025. This is 89% below median its historical median of 6.89. Over the past decade, Newron Pharmaceuticals SpA's Current Ratio has ranged from 0.68 to 15.40. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #1239 out of 1412 companies in the Biotechnology industry, placing it in the top 87.7%.
Is Newron Pharmaceuticals SpA's Current Ratio too high?
Newron Pharmaceuticals SpA's current Current Ratio of 0.76 is 89% below median its 10-year median of 6.89. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 15.40. The Biotechnology industry median Current Ratio is 3.89. Newron Pharmaceuticals SpA's value of 0.76 is 80.5% below this industry median. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #1239 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #1239 out of 1412 companies for Current Ratio. This places Newron Pharmaceuticals SpA in the lower half of its industry. The industry median Current Ratio is 3.89. Newron Pharmaceuticals SpA's value of 0.76 is 80.5% below this benchmark. Historically, Newron Pharmaceuticals SpA's own Current Ratio has ranged from 0.68 to 15.40 over the past decade. While the company's 10-year median is 6.89 vs. the industry median of 3.89, Newron Pharmaceuticals SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newron Pharmaceuticals SpA's current Current Ratio of 0.76 is 80.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current Current Ratio is 0.76, which is 89% below median its own 10-year median of 6.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF12.92, compared to a current price of CHF12.64 — trading 2.2% below its estimated fair value. The current Current Ratio is 0.76, which is 89% below median its 10-year median of 6.89 and 80.5% below the Biotechnology industry median of 3.89. Newron Pharmaceuticals SpA's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Current Ratio is 0.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of CHF12.64 is trading 2.2% below its estimated GF Value™ of CHF12.92.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for XSWX:NWRN:
Current Ratio: 0.76 (89% below median its 10-year median of 6.89)
GF Value™: CHF12.92 vs. price of CHF12.64 (2.2% below fair value)
Industry Position: 80.5% below the Biotechnology median (#1239 of 1412)
No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
62GF Score
Get the complete analysis for XSWX:NWRN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NWRN has been successfully added to your 
